Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Gyo Asai"'
Autor:
Tatsuro Fukuhara, Haruhiro Saito, Naoki Furuya, Kana Watanabe, Shunichi Sugawara, Shunichiro Iwasawa, Yoshio Tsunezuka, Ou Yamaguchi, Prof Morihito Okada, Kozo Yoshimori, Ichiro Nakachi, Prof Akihiko Gemma, Koichi Azuma, Futoshi Kurimoto, Yukari Tsubata, Yuka Fujita, Hiromi Nagashima, Gyo Asai, Satoshi Watanabe, Masaki Miyazaki, Prof Koichi Hagiwara, Prof Toshihiro Nukiwa, Prof Satoshi Morita, Prof Kunihiko Kobayashi, Prof Makoto Maemondo
Publikováno v:
EBioMedicine, Vol 57, Iss , Pp 102861- (2020)
Summary: Background: The NEJ026 Phase 3 study demonstrated that erlotinib and bevacizumab (BE)-treated NSCLC patients with EGFR mutations had significantly better progression-free survival (PFS) than those treated with erlotinib alone (E). This study
Externí odkaz:
https://doaj.org/article/6f1997f9abf34fafabd3f2040e531e6b
Autor:
Shimaa Nour Moursi Ahmed, Potjanee Korrungruang, Hideo Saka, Gyo Asai, Yuko Ise, Chiyoe Kitagawa, Masahide Oki
Publikováno v:
Case Reports in Medicine, Vol 2015 (2015)
We report a case of posttuberculosis (TB) tracheobronchial stenoses presented with progressive exertional dyspnea during the course of anti-TB treatment. An 83-year-old Japanese man was admitted for progressive dyspnea; chest X-ray and CT showed sten
Externí odkaz:
https://doaj.org/article/14aff4e97bc24efe8d79533123e1550f
Autor:
Kunihiko Kobayashi, Hiromi Nagashima, Gyo Asai, Yosuke Kawashima, Shunichi Sugawara, Kana Watanabe, Naoki Furuya, Masahiro Seike, Ichiro Nakachi, Koichi Azuma, Satoshi Watanabe, Morihito Okada, Ou Yamaguchi, Yoshio Tsunezuka, Yukari Tsubata, Haruhiro Saito, Makoto Maemondo, Koichi Hagiwara, Masaki Miyazaki, Shunichiro Iwasawa, Kozo Yoshimori, Futoshi Kurimoto, Yuka Fujita, Toshihiro Nukiwa, Satoshi Morita, Tatsuro Fukuhara
Publikováno v:
The Lancet Respiratory Medicine. 10:72-82
Summary Background Bevacizumab is a promising candidate for combination treatment with epidermal growth factor receptor tyrosine-kinase inhibitors (eg, erlotinib), which could improve outcomes for patients with metastatic EGFR-mutant non-small-cell l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e06dbd6beba5b3e41be5f0ed8a144eb5
https://doi.org/10.1016/s2213-2600(21)00166-1
https://doi.org/10.1016/s2213-2600(21)00166-1
Autor:
Yoshio Tsunezuka, Kozo Yoshimori, Kunihiko Kobayashi, Satoshi Watanabe, Futoshi Kurimoto, Yuka Fujita, Ou Yamaguchi, Makoto Maemondo, Yukari Tsubata, Kana Watanabe, Toshihiro Nukiwa, Gyo Asai, Tatsuro Fukuhara, Satoshi Morita, Koichi Azuma, Masaki Miyazaki, Akihiko Gemma, Naoki Furuya, Hiromi Nagashima, Morihito Okada, Haruhiro Saito, Ichiro Nakachi, Shunichi Sugawara, Koichi Hagiwara, Shunichiro Iwasawa
Publikováno v:
The Lancet Oncology. 20:625-635
Summary Background Resistance to first-generation or second-generation EGFR tyrosine kinase inhibitor (TKI) monotherapy develops in almost half of patients with EGFR-positive non-small-cell lung cancer (NSCLC) after 1 year of treatment. The JO25567 p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55f9e96a0e228ab3abfa528167f559dd
https://doi.org/10.1016/s1470-2045(19)30035-x
https://doi.org/10.1016/s1470-2045(19)30035-x
Autor:
Kunihiko Kobayashi, Ichiro Nakachi, Masahiro Seike, Yoshio Tsunezuka, Masaki Miyazaki, Haruhiro Saito, Hiromi Nagashima, Satoshi Watanabe, Morihito Okada, Ou Yamaguchi, Tatsuro Fukuhara, Satoshi Morita, Gyo Asai, Makoto Maemondo, Yukari Tsubata, Toshihiro Nukiwa, Koichi Hagiwara, Koichi Azuma, Shunichiro Iwasawa, Kozo Yoshimori, Kana Watanabe, Futoshi Kurimoto, Yuka Fujita, Shunichi Sugawara, Yosuke Kawashima, Naoki Furuya
Publikováno v:
SSRN Electronic Journal.
Background: In NEJ026, a phase III trial comparing bevacizumab plus erlotinib (BE) to erlotinib alone (E) for advanced EGFR-mutant non-small-cell lung cancer (NSCLC), we demonstrated that the progression-free survival (PFS) of BE was significantly su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c6f9a02e1fec0decf54c9ddce06d673
https://doi.org/10.2139/ssrn.3770676
https://doi.org/10.2139/ssrn.3770676
Autor:
Chiaki, Kondo, Gyo, Asai
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 47(6)
Superior vena cava(SVC)syndrome is a syndrome caused by impaired venous return due to stenosis of the SVC. Most of such cases are due to tumors(non-small cell lungcancer, small cell lungcancer, malignant lymphoma, etc), and the most common cause of S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::13c3db220ee7a80010cc02ce19b45e42
https://pubmed.ncbi.nlm.nih.gov/32541158
https://pubmed.ncbi.nlm.nih.gov/32541158
Autor:
Kozo Yoshimori, Yoshio Tsunezuka, Koichi Azuma, Akihiko Gemma, Futoshi Kurimoto, Satoshi Watanabe, Shunichi Sugawara, Satoshi Morita, Ichiro Nakachi, Kunihiko Kobayashi, Yuka Fujita, Naoki Furuya, Kana Watanabe, Makoto Maemondo, Toshihiro Nukiwa, Naoto Morikawa, Gyo Asai, Koichi Hagiwara, Morihito Okada, Masaki Miyazaki, Yukari Tsubata, Ou Yamaguchi, Shunichiro Iwasawa, Tatsuro Fukuhara, Haruhiro Saito
Publikováno v:
SSRN Electronic Journal.
Background: Resistance to first- or second-generation TKI monotherapy, the standard treatment for EGFR mutation-positive NSCLC, develops in less than a year. A phase II study comparing combination therapy of erlotinib and bevacizumab (BE) with erloti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e23256ee1748917a8faed2d9a718c7e
https://doi.org/10.2139/ssrn.3271416
https://doi.org/10.2139/ssrn.3271416
Autor:
Shigeru Tanaka, Masaru Kondou, Satoshi Katsuno, Norihiro Takahara, Shuuhei Hayashi, Yuuta Kashiwagi, Nobuaki Mukouyama, Hidehito Tanaka, Eiichi Maruyama, Gyo Asai, Masataka Tamura, Shin Yamada, Shouei You
Publikováno v:
Annals of Oncology. 30:vi135
Background The pathway consisting of the receptor programmed cell death 1 (PD-1) and its ligands plays a crucial role to escape T cell-mediated immunity. Antibodies targeting PD-1 and its ligands have beneficial antitumor effects on many cancers, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abe3d87d2c6b278db0d471fc7a279576
https://doi.org/10.1093/annonc/mdz343.081
https://doi.org/10.1093/annonc/mdz343.081
Autor:
Hisao Uejima, Kenji Tamura, Kazuhiko Nakagawa, Takayasu Kurata, Masahiro Fukuoka, Gyo Asai, Nobuyuki Yamamoto
Publikováno v:
Journal of Thoracic Oncology. 1:226-230
The purpose of this study was to investigate the maximum tolerated doses, dose-limiting toxicities, efficacy, and pharmacokinetic profiles in the combination of irinotecan and paclitaxel. Eligibility criteria included age 75 years or younger, good pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::790aaf25431cf91a03f4ddcefb6ba6f3
https://doi.org/10.1016/s1556-0864(15)31572-0
https://doi.org/10.1016/s1556-0864(15)31572-0
Autor:
Masahide Oki, Gyo Asai, Chiyoe Kitagawa, Hideo Saka, Yuko Ise, Potjanee Korrungruang, Shimaa Nour Moursi Ahmed
Publikováno v:
Case Reports in Medicine
Case Reports in Medicine, Vol 2015 (2015)
Case Reports in Medicine, Vol 2015 (2015)
We report a case of posttuberculosis (TB) tracheobronchial stenoses presented with progressive exertional dyspnea during the course of anti-TB treatment. An 83-year-old Japanese man was admitted for progressive dyspnea; chest X-ray and CT showed sten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fe1c1efe89c03dfecc0991ebeb761e4
https://pubmed.ncbi.nlm.nih.gov/25873975
https://pubmed.ncbi.nlm.nih.gov/25873975